Currently Empty: $0.00
Precision Pen cartridgeSubcutaneous (SQ)40 mg
An investigational triple receptor agonist in late-stage clinical development, producing the largest weight reductions reported for any pharmacological agent to date.
Delivery and return
Delivery and return
| Standard Delivery (Signed for) | Delivered within 3-5 working days |
| Express Delivery (Standard Parcels) | Delivered within 1-2 working days |
| Extra-Large Parcels (Signed for) | Delivered within 3-5 working days |
| Furniture | Delivery usually takes place within 2 weeks. |
Shipping Information
Shipping Information
Free Shipping
Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).Drop Shipping
We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.Ground Shipping
Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.Composition and care
Composition and care
We speak a lot about the importance of gut health—not only for beauty—but also in terms of our overall health, wellbeing and immunity. But before we can fully understand why the gut is so integral to our health, it’s first essential to learn more about the physiology of the gut itself—and how it works.
Research Handling Note
Allow sealed vials to equilibrate to ambient laboratory temperature before opening. This helps minimise the risk of condensation forming within the vial. Keep unopened vials stored at 2-8 C, protected from direct light and moisture. All handling, storage after opening, and laboratory procedures should be carried out according to the receiving laboratory’s established protocols and applicable requirements.
Retatrutide is a single-molecule agonist at three receptors – GIP, GLP-1 and glucagon – and represents the most advanced iteration of the incretin class. Its Phase II obesity results, published in 2023, reported mean weight reductions substantially exceeding those of dual agonists, and it is currently in Phase III. It is essential to be clear about its status: retatrutide is an investigational medicine that has not been approved by any regulator, its long-term safety profile is not established, and the compound remains under active development by its originator. Material supplied outside that development programme is not the investigational medicinal product used in those trials, and the trial results cannot be attributed to it. This SKU carries significant regulatory and intellectual property exposure and should not be listed without legal review.
Active Compound: Retatrutide (GGG tri-agonist: GIP / GLP-1 / glucagon receptor)
Permitted Claim GuidelinesAn investigational triple receptor agonist currently in clinical development. Not an approved medicine. Supplied only on documented practitioner direction where permitted.
Mechanism of Action
Simultaneous agonism at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. GLP-1 and GIP activity reduce appetite, slow gastric emptying and enhance glucose-dependent insulin secretion; glucagon receptor agonism additionally increases energy expenditure and promotes hepatic fat mobilisation. The glucagon component distinguishes it from dual agonists.
Evidence Grade: B - Phase II data published, Phase III ongoing; investigational, not approved
Clinical Evidence BasePhase II randomised placebo-controlled trials in obesity and type 2 diabetes reported substantial, dose-dependent weight reduction and glycaemic improvement. Phase III programmes are ongoing. No regulatory approval anywhere; long-term safety and cardiovascular outcome data are not yet available.
Literature & ReferencesJastreboff AM et al. N Engl J Med, 2023 - triple-hormone-receptor agonist retatrutide for obesity, Phase 2 trial. | Rosenstock J et al. Lancet, 2023 - retatrutide in patients with type 2 diabetes, Phase 2 trial. | Coskun T et al. Cell Metab, 2022 - LY3437943, a novel GIP, GLP-1 and glucagon receptor tri-agonist.
Safety & Precautions
Class effects are gastrointestinal and dose-related: nausea, vomiting, diarrhoea and constipation, most pronounced during dose escalation. Reported class risks include pancreatitis, gallbladder disease and cholelithiasis with rapid weight loss, and dehydration with consequent renal impairment. Rodent studies of the GLP-1 class show thyroid C-cell tumours; the class is contraindicated with personal or family history of medullary thyroid carcinoma or MEN2. Increased heart rate has been observed. Contraindicated in pregnancy. Loss of lean mass alongside fat mass requires attention to protein intake and resistance training.
ContraindicationsPersonal or family history of medullary thyroid carcinoma; multiple endocrine neoplasia type 2; history of pancreatitis; pregnancy and breastfeeding; severe gastrointestinal disease including gastroparesis; known hypersensitivity. Caution with insulin or sulfonylureas due to hypoglycaemia risk.
Storage & HandlingStore lyophilised vial or cartridge at 2-8 C, protected from light. Do not freeze.
Regulatory Status
Investigational medicinal product under active development. Not approved by any regulator. Supply outside a clinical trial raises significant regulatory, product liability and intellectual property considerations that require legal review before any listing.
